Antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium -Octreotate randomized vs Sunitinib in unresctable progressive well-differentiated neuroendocrine pancreatic carcinoma : first randomized phase II . OCLURANDOM1 in pNET

assignment_turned_inproject

Funder: Institut National du CancerProject code: INCa-DGOS-5588 Call for proposal: PHRC12

Funded under: PHRC

Antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium -Octreotate randomized vs Sunitinib in unresctable progressive well-differentiated neuroendocrine pancreatic carcinoma : first randomized phase II . OCLURANDOM1 in pNET

- Summary
- DMPs

Partners

CHUG , Institut Gustave Roussy , Institut Claudius Regaud , CHU , CHU Marseille - Hôpital la Timone , Hôpital Claude Huriez , Hôpital Louis Pradel , Hôpital Haut-Lévêque , Hôpital Beaujon

Data Management Plans

Start a new DMP in Argos

Found an issue? Give us feedback

Select content type to embed

All Research products

arrow_drop_down

<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=inca________::770450295cdce5074d94b281f077f41f&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

Antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium -Octreotate randomized vs Sunitinib in unresctable progressive well-differentiated neuroendocrine pancreatic carcinoma : first randomized phase II . OCLURANDOM1 in pNET

Antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium -Octreotate randomized vs Sunitinib in unresctable progressive well-differentiated neuroendocrine pancreatic carcinoma : first randomized phase II . OCLURANDOM1 in pNET

Loading